Compare Aurobindo Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DR. REDDYS LAB - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DR. REDDYS LAB AUROBINDO PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 11.0 21.5 51.5% View Chart
P/BV x 2.4 3.2 74.7% View Chart
Dividend Yield % 0.5 0.7 70.9%  

Financials

 AUROBINDO PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
DR. REDDYS LAB
Mar-19
AUROBINDO PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs8092,875 28.1%   
Low Rs5041,888 26.7%   
Sales per share (Unadj.) Rs281.1930.2 30.2%  
Earnings per share (Unadj.) Rs41.4117.4 35.2%  
Cash flow per share (Unadj.) Rs50.9185.8 27.4%  
Dividends per share (Unadj.) Rs2.5020.00 12.5%  
Dividend yield (eoy) %0.40.8 45.3%  
Book value per share (Unadj.) Rs199.4844.4 23.6%  
Shares outstanding (eoy) m585.88166.07 352.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.32.6 91.2%   
Avg P/E ratio x15.920.3 78.3%  
P/CF ratio (eoy) x12.912.8 100.6%  
Price / Book Value ratio x3.32.8 116.8%  
Dividend payout %6.017.0 35.5%   
Avg Mkt Cap Rs m384,630395,496 97.3%   
No. of employees `00017.322.0 78.9%   
Total wages/salary Rs m21,30833,562 63.5%   
Avg. sales/employee Rs Th9,500.77,032.8 135.1%   
Avg. wages/employee Rs Th1,229.41,527.9 80.5%   
Avg. net profit/employee Rs Th1,397.9887.7 157.5%   
INCOME DATA
Net Sales Rs m164,666154,482 106.6%  
Other income Rs m1,0203,375 30.2%   
Total revenues Rs m165,686157,857 105.0%   
Gross profit Rs m37,71831,782 118.7%  
Depreciation Rs m5,58011,348 49.2%   
Interest Rs m777889 87.4%   
Profit before tax Rs m32,38022,920 141.3%   
Minority Interest Rs m310-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1833,858 212.1%   
Profit after tax Rs m24,22919,500 124.3%  
Gross profit margin %22.920.6 111.3%  
Effective tax rate %25.316.8 150.1%   
Net profit margin %14.712.6 116.6%  
BALANCE SHEET DATA
Current assets Rs m121,878111,101 109.7%   
Current liabilities Rs m86,80658,973 147.2%   
Net working cap to sales %21.333.7 63.1%  
Current ratio x1.41.9 74.5%  
Inventory Days Days13079 163.7%  
Debtors Days Days6894 72.6%  
Net fixed assets Rs m81,037101,245 80.0%   
Share capital Rs m586830 70.6%   
"Free" reserves Rs m116,218139,406 83.4%   
Net worth Rs m116,804140,236 83.3%   
Long term debt Rs m4,51222,000 20.5%   
Total assets Rs m211,052224,656 93.9%  
Interest coverage x42.726.8 159.3%   
Debt to equity ratio x00.2 24.6%  
Sales to assets ratio x0.80.7 113.5%   
Return on assets %11.89.1 130.6%  
Return on equity %20.713.9 149.2%  
Return on capital %27.414.9 183.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72788,673 91.0%   
Fx outflow Rs m34,70019,104 181.6%   
Net fx Rs m46,02769,569 66.2%   
CASH FLOW
From Operations Rs m19,54828,704 68.1%  
From Investments Rs m-19,570-7,727 253.3%  
From Financial Activity Rs m8,642-21,326 -40.5%  
Net Cashflow Rs m8,922-314 -2,841.4%  

Share Holding

Indian Promoters % 54.1 25.5 212.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 5.4 147.2%  
FIIs % 27.7 35.3 78.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.2 15.3 66.7%  
Shareholders   69,601 75,885 91.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ALEMBIC LTD  SUN PHARMA  PFIZER  GLENMARK PHARMA  SHASUN PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Telecom and Automobiles Stocks Lose(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.1% while the Hang Seng is down 0.1%.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 18, 2019 11:53 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ALEMBIC LTD COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS